The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Department of Oncology, Jiaxing, China.
The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Department of Oncology, Jiaxing, China.
Ann Hepatol. 2022 Jul-Aug;27(4):100701. doi: 10.1016/j.aohep.2022.100701. Epub 2022 Mar 26.
Hepatocellular carcinoma (HCC) ranks third on the list of the leading cause for cancer death globally. The treatment of HCC patients is unsatisfactory. However, the traditional Chinese medicine Chebulae Fructus has potential efficacy in the treatment of HCC.
We mined the active ingredients of Chebulae Fructus and its main targets from the Traditional Chinese Medicine Systems Pharmacology database. HCC-related datasets were downloaded from The Cancer Genome Atlas database and differentially expressed genes (DEGs) in HCC were obtained by differential expression analysis. Top10 small molecule compounds capable of reversing HCC pathology were screened by the Connectivity Map database based on DEGs. Ellipticine, an extract of Chebulae Fructus, had the potential to reverse HCC pathology. Protein-Protein Interaction (PPI) networks of DEGs in HCC were constructed using STRING. Eighteen potential targets of Chebulae Fructus for the treatment of HCC were obtained by taking intersection of DEGs in HCC with targets corresponding to the active constituents of Chebulae Fructus. In addition, MTT assay was also employed to examine the effect of ellipticine on HCC cell viability.
It has been shown that ellipticine and ellagic acid have antitumor activity. Random Walk with Restart analysis of PPI networks was performed using potential targets as seeds, and the genes with the top 50 affinity coefficients were selected to construct a drug-active constituent-gene interaction network. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses of key genes involved in the treatment of HCC with Chebulae Fructus demonstrated that these genes were mainly enriched in signaling pathways related to tumor metabolism such as cAMP signaling pathway and Ras signaling pathway. Finally, it was verified by MTT assay that proliferation of HCC cells could be remarkably hindered.
We excavated ellipticine, a key active constituent of Chebulae Fructus, by network pharmacology, and elucidated the signaling pathways involved in Chebulae Fructus, providing a theoretical basis for the use of Chebulae Fructus for HCC clinical application.
肝细胞癌(HCC)在全球癌症死亡原因中排名第三。HCC 患者的治疗效果并不令人满意。然而,中药诃子具有治疗 HCC 的潜力。
我们从中药系统药理学数据库中挖掘诃子的活性成分及其主要靶点。从癌症基因组图谱数据库中下载 HCC 相关数据集,并通过差异表达分析获得 HCC 中的差异表达基因(DEGs)。基于 DEGs,通过连接图谱数据库筛选出能够逆转 HCC 病理的前 10 种小分子化合物。诃子提取物野靛碱具有逆转 HCC 病理的潜力。使用 STRING 构建 HCC 中 DEGs 的蛋白质-蛋白质相互作用(PPI)网络。通过 HCC 中 DEGs 与诃子活性成分对应的靶点取交集,获得 18 个诃子治疗 HCC 的潜在靶点。此外,还采用 MTT 法检测野靛碱对 HCC 细胞活力的影响。
表明野靛碱和鞣花酸具有抗肿瘤活性。以潜在靶点为种子,对 PPI 网络进行随机游走重新启动分析,选择具有前 50 个亲和力系数的基因构建药物-活性成分-基因相互作用网络。对诃子治疗 HCC 的关键基因进行基因本体论和京都基因与基因组百科全书富集分析表明,这些基因主要富集在与肿瘤代谢相关的信号通路中,如 cAMP 信号通路和 Ras 信号通路。最后,MTT 试验验证了诃子对 HCC 细胞增殖的显著抑制作用。
我们通过网络药理学挖掘了诃子的关键活性成分野靛碱,并阐明了诃子参与的信号通路,为诃子在 HCC 临床应用提供了理论依据。